What this covers

Oncologist and epidemiologist Vinayak Prasad sits down with Russ Roberts to diagnose a dysfunction in pharmaceutical approval and pricing. Prasad argues that the FDA now approves cancer drugs with minimal survival benefit—a median of 2.1 months—because it relies on uncontrolled trials measuring tumor shrinkage rather than actual patient survival. The result is that expensive, marginally beneficial drugs monopolize subsidized spending while crowding out the care patients would genuinely prefer. Prasad traces this breakdown to a deeper cultural problem: a death of duty in which actors across medicine, academia, and regulation serve themselves rather than their actual obligations. The conversation moves between technical problems in drug approval and broader failures of professional integrity.

Prasad illustrates specific failures through cases like melflufen, approved on an uncontrolled study, then shown in a randomized trial to offer no survival benefit and possibly harm. He contrasts this against transformational drugs like Gleevec, which restored near-normal life expectancy to chronic myeloid leukemia patients. On the structural side, he examines regulatory capture—the FDA increasingly viewing pharma companies as its client rather than the public—and the revolving door by which reviewers later join industry boards. He also critiques academic medicine's complicity: universities have abandoned their truth-seeking mission for pharma partnerships and IP ventures, leaving no credible voice to challenge the system. Roberts adds that opportunity cost is obscured when taxpayers subsidize marginal drugs rather than care patients value more. The pair also discuss how concentrated benefits, diffuse costs allows industry advocates to outmatch the disinterested public, and touch on medicine's broader identity crisis between shift-based work and professional obligation.

Sharpest takeaway

Prasad argues that the FDA's lowered approval bar lets pharmaceutical companies bring marginally beneficial, expensive cancer drugs to market and monopolize subsidized spending, and that this dysfunction—along with academic silence and broader social failures—reflects a deeper 'death of duty' in which actors serve themselves rather than the people they are obligated to.

  • The median cancer drug approval improves survival by only ~2.1 months, and approvals often rely on uncontrolled trials measuring tumor shrinkage rather than survival
  • Subsidizing marginal drugs crowds out spending on care that patients would actually prefer, and removes the trade-off from patients' view
  • FDA capture, academic dependence on pharma funding, and a cultural decline of duty all enable the system to persist unchallenged

The argument · threads3 threads · 34 claims
0.85

Profit incentives in pharmaceutical markets create monopoly pricing that American taxpayers subsidize globally while universities and economists silence themselves to protect career advancement.

4 pointscentrality 5/5
  • A small survival improvement entitles a new drug to effectively monopolize the market and lofty pricing, while the predecessor drug that worked almost as well is no longer subsidized and is therefore taken off the table, granting the latest drug monopoly power.

    “that small improvement often entitles a drug to effectively monopolize the market. And, the drug that worked just almost nearly as well is now not subsidized at all and is therefore off the table, giving the latest drug essentially monopoly power.”

  • An enormous portion of pharmaceutical profitability comes from unconstrained pricing that Medicare pays out of American taxpayers' pockets; other countries (Israel, France, England, Romania) pay far less, so the drug would not exist without the large profit opportunity in America, meaning US taxpayers effectively subsidize cheaper drugs worldwide.

    “An enormous portion of the profitability in the drug market comes from the unconstrained pricing that Medicare pays for, that comes out of the pocket of American taxpayers, that benefits people all over the world because they get a different price. And, that drug wouldn't exist without that enormous opportunity in America”

  • It used to be that universities cared about truth, but the academic and government grant system has evolved to reward people who play by the rules and pursue the next career step rather than seek the truth, producing a subtle corrosion of values that money causes when one is not careful.

    “it used to be that universities cared about truth. And that got too expensive... it's just a subtle corrosion of values that money can do if you're not careful. And, the system has evolved... to reward people who play by the rules rather than seek the truth.”

  • About half of American macroeconomists believe they are in the top 10% and could be Fed Chair someday, so they never say anything critical of the Fed—a parallel form of value-corroding self-interest that mirrors academic medicine's silence on pharma.

    “the number of economists who think they could be Chair of the Fed someday is enormously large. About half the macroeconomists in America think they're in the top 10%. So... they never say anything critical of the Fed.”

0.56

Professional duty demands showing up despite discomfort because irreplaceability creates obligation that transcends personal wellbeing.

2 pointscentrality 4/5
  • What makes a doctor's job profound is being the only person who can have a particular meaningful conversation with a patient—there is nobody to cover for you and nobody the patient wants to hear it from—so the irreplaceability is precisely what creates the obligation to show up regardless of how you feel.

    “Because you are the only person, because you have the chance to have that very meaningful and profoundly, often satisfying, gratifying, poignant, painful, deep, intense interaction with another human being, you've got to show up. That's the deal.”

  • A culture that says you can sit out whenever you don't feel 100% generates worse results than one demanding you overcome what's on your mind; day-to-day wellbeing is overrated because many things—dignity, pride, principles, duty—matter more than how you feel on a given day.

    “the privileging of our day-to-day wellbeing, which I've argued is a little bit overrated. There are many, many things more important than our day-to-day wellbeing: our dignity, our pride, our principles”

0.35

Modern culture punishes minor transgressions harshly while refusing to shame failures of duty, inverting healthy moral judgment.

1 pointcentrality 3/5
  • Modern Western culture is paradoxically quick to ruin someone's life over one small mistake yet uncomfortable shaming people for failures of duty; the willingness to judge and impose shame—what Adam Smith called the desire to be not merely praised but praiseworthy—has fallen out of fashion in face-to-face culture even as it runs rampant on social media.

    “we live in this strange time where we're incredibly critical and one very small mistake can ruin a person's life through the public response to it. At the same time, we're very uncomfortable shaming people for their lack of duty.”